H.C. Wainwright reiterated its Buy rating and $29.00 price target for 89bio Inc . (NASDAQ:ETNB) shares. According to InvestingPro data, the stock currently trades at $6.31, near its 52-week low of $5.
Weiss Ratings reiterated their sell (d-) rating on shares of 89bio (NASDAQ:ETNB – Free Report) in a research note released on Saturday,Weiss Ratings reports. A number of other research analysts also ...
Inc. (NASDAQ:ETNB – Get Free Report)’s share price hit a new 52-week low during trading on Friday following insider selling activity. The stock traded as low as $5.99 and last traded at $6.09, with a ...
Decades since Elvis Presley dominated the music charts, children are among those celebrating the King of Rock and Roll. The Parkes Elvis Festival has returned for another year and there are dozens ...
Nguyen Quoc, the Chief Technical Operations Officer at 89bio, Inc. (NASDAQ:ETNB), has sold shares worth approximately $71,149, according to a recent SEC filing. The transaction comes as the stock ...
Leerink Partners analyst Thomas Smith has maintained their bullish stance on ETNB stock, giving a Buy rating on January 2.Stay Ahead of the ...
Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.
Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...
(ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe ...
Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 – – The Phase 3 ENLIGHTEN program in ...
MARKHAM, Ontario, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare” or the "Company”) (TSX: EXE) announced today that it plans to release its financial results for the fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback